HELSINN HEALTHCARE, Switzerland.
Now in its fourth decade, the Helsinn Group is one of the world’s leading companies in supportive cancer care. Their business model is built on forging lasting alliances with worldwide partners who share their vision. Through a mix of integrated early and late stage licensing programs and their own developments, Helsinn have developed a comprehensive portfolio of effective pharmaceuticals and specialist therapies that are sold in over 90 countries. These also include a late stage pipeline of future cancer therapies, which will cater unmet medical needs in the treatment of cancer especially Chemo-Induced-Nausea-and-Vomiting (CINV), Chemo-Induced-Diarrhea and Anorexia-Cachexia in non-small cell lung cancer patients.
Pharma Solutions is licensed for marketing Gelclair® in MENA countries including UAE, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, Jordan, Lebanon, Egypt, Algeria, Iraq, Libya and Morocco.